Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Down 27.9% in January

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 481,400 shares, a decrease of 27.9% from the January 15th total of 667,900 shares. Based on an average trading volume of 612,900 shares, the short-interest ratio is currently 0.8 days.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC boosted its position in Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock valued at $1,727,000 after buying an additional 33,196 shares during the period. Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth $729,000. Virtu Financial LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth $170,000. Northern Trust Corp lifted its position in shares of Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares during the last quarter. Finally, Atria Investments Inc lifted its position in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares during the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Monday, January 27th.

Milestone Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ:MIST traded down $0.02 during mid-day trading on Friday, reaching $2.27. 529,534 shares of the company were exchanged, compared to its average volume of 680,388. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The firm has a market cap of $121.05 million, a price-to-earnings ratio of -2.80 and a beta of 1.80. The firm’s 50-day simple moving average is $2.03 and its 200 day simple moving average is $1.72. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.